Table 1:

Clinicopathologic comparison of IMAs with KRAS mutations, NRG1 fusions, and other alterations

	KRAS N=104	NRG1 N=12	Other N=28	p value for KRAS+ vs NRG1+
Age at Diagnosis, years
Range	27 – 89	37 – 84	34 – 89
Median	67	69	62	0.58
Sex
Female	71 (68%)	6 (50%)	14 (50%)
Male	33 (32%)	6 (50%)	14 (50%)	0.21
Smoking status
Heavy smoker	41 (39%)	2 (17%)	6 (21%)
Light smoker (≥15 PY)	38 (37%)	4 (33%)	8 (29%)
Never	25 (24%)	6 (50%)	14 (50%)	0.12
Pack years
Range	0 – 120	0 – 43	0 – 80
Mean	20.0	5.9	11.3	0.040
Stage at Baseline
I	53 (51%)	2 (17%)	11 (39%)
II	23 (22%)	3 (25%)	2 (7%)
III	17 (16%)	5 (41%)	6 (22%)
IV	11 (11%)	2 (17%)	9 (32%)	0.08
Surgically Resected Ever
Yes	92 (88%)	10 (83%)	18 (64%)
No	12 (12%)	2 (17%)	10 (36%)	0.63
Metastatic disease
Yes	33 (32%)	8 (67%)	17 (61%)
No	71 (68%)	4 (33%)	11 (39%)	0.016
Site of metastasis
Intrathoracic only	28 (27%)	2 (17%)	12 (43%)
Intrathoracic + Extrathoracic	5 (5%)	6 (50%)	5 (18%)	0.0006
Histologic type
Pure IMA	92 (88%)	10 (83%)	13 (46%)
Mixed IMA	12 (12%)	2 (17%)	15 (54%)	0.61
Primary Tumor Size, cm
Range	0.3 – 19.5	2.5 – 15.5	0.4 – 15.5
Mean	3.9	7.7	5.5	0.0004
Aggressive histologic features (tumor necrosis or desmoplastic stromal invasion)
Present	56 (54%)	11 (92%)	17 (61%)
Absent	48 (46%)	1 (8%)	11 (39%)	0.012